CD274 and non-small cell lung carcinoma: Recently, the use of immune checkpoint inhibitors (ICIs) has greatly altered the standard of care for patients with advanced NSCLC without targetable EGFR or ALK genetic aberrations depending on the patient’s PD-L1 expression level.